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Abstract 
Depression is a chronic, recurring illness that affects more than 120 million 
people worldwide.  Drugs increasing the synaptic availability of serotonin and 
norepinephrine (biogenic amine-based agents) have been used to treat 
depression for more than 50 years.  However, significant symptom improvement 
requires ≥2-4 weeks of treatment, and a first course of therapy provides symptom 
relief to only 60-65% of patients.  Roche and Evotec recently announced plans to 
develop N-methyl-D-aspartate (NMDA) receptor antagonists targeting the NR2B 
subtype for treatment resistant depression. This announcement closely follows a 
report that another NR2B antagonist, traxoprodil (CP 101,606), is antidepressant 
in patients unresponsive to a serotonin selective reuptake inhibitor (SSRI) as well 
as reports of rapid and sustained antidepressant effects following a single 
injection of the NMDA antagonist, ketamine.  Here we describe evidence that 
glutamate-based therapies may represent an effective alternative to biogenic-
amine based agents for depression, and provide perspectives on developing 
these agents.  
Comment [E1]: Full form on first use. 
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Introduction 
Major depressive disorder (depression) is characterized by the core 
symptoms of depressed mood and a loss of interest and/or pleasure. Other 
symptoms that may be manifested include significant weight changes (loss or 
gain), sleep disturbances (insomnia or hypersomnia), fatigue or loss of energy, 
diminished ability to think or concentrate, feelings of worthlessness or guilt, 
recurrent thoughts of death or suicide, and psychomotor agitation or retardation.  
In industrialized societies, approximately 5% of the population experienced a 
major depressive episode (MDE, defined as the occurrence of a core symptom 
and 4 or more other symptoms daily or almost daily for ≥2 weeks [1]) in the past 
year [2]. In addition to producing clinically significant distress, an MDE is almost 
uniformly accompanied by some degree of social and/or occupational 
impairment, negatively impacting quality of life and contributing to the societal 
burden associated with loss of work and health care costs. Evidence from twin 
and family studies indicates there is a prominent genetic contribution to 
depression [3,4].  However, no genes putting individuals at risk for depression 
have been unequivocally identified, despite extensive candidate gene association 
studies and genome-wide linkage scans [5,6].  This should not be viewed as 
surprising given the absence of definitive biological markers, variable diagnostic 
criteria (including diametrically opposed symptoms) that wax and wane over time, 
and environmentally-induced epigenetic reprogramming that can alter gene 
expression [7,8].   
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Drugs that increase the synaptic availability of biogenic amines have been 
used to treat depression for more than 50 years.  Currently, the most widely used 
biogenic-amine based agents selectively block the uptake of serotonin and/or 
norepinephrine.  These compounds are generally safer and easier to use than 
older, biogenic-amine based drugs (e.g. monoamine oxidase inhibitors and 
tricyclics) but do not address the principal therapeutic drawbacks that appears 
inherent to this mechanism [9,10].  Thus, in placebo controlled trials, these drugs 
require 2-4 (or more) weeks to produce a clinically meaningful improvement in 
depressive symptomatology. This delayed onset may have dire consequences 
for patients with suicidal ideation (~15% of depressed individuals commit suicide) 
and can negatively impact patient compliance.  Moreover, only 60-65% of 
patients respond to the initial regimen, and among those responding, less than 
half either reach remission or become symptom free [10].  Individuals not 
responding to a first course of AD are often switched to a different drug, with 
results that are generally modest and incremental [11].  
NMDA antagonists exhibit AD-like actions in preclinical models 
The hypothesis that NMDA antagonists are antidepressant was based on 
observations that exposure to inescapable, but not escapable shock disrupted 
hippocampal long term potentiation [12], a phenomenon that is dependent on 
NMDA receptor activation [13,14]. The uncontrollable nature of this inescapable 
stress protocol [12] affects neurotransmitter systems associated with the action 
of antidepressant drugs [15,16] and also produces “learned helplessness” 
[17,18], a behavioral syndrome that is blocked by antidepressants [19].  Based 
Comment [E2]: More information required here 
for the benefit of the general reader. Please include a 
new BOX on mechanisms underlying learned 
helplessness. 
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on these findings, it was hypothesized that the pathways subserved by NMDA 
receptors were also critical in eliciting the behavioral deficits (i.e., learned 
helplessness) induced by inescapable stressors, and that interfering with these 
pathways (by using NMDA antagonists) would, like biogenic amine-based 
antidepressants (ADs), mitigate these behavioral deficits [20], see Fig. 1.  
Moreover, it was hypothesized that if neuroadaptive changes must precede the 
therapeutic effects of biogenic amine-based ADs (that is, the ≥2-4 week delay in 
onset of action), then inhibition of NMDA receptor function could result in a direct 
and more efficacious AD action [21]. 
The initial test of the hypothesis that NMDA antagonists are 
antidepressant examined the prototypic use dependent channel blocker, 
dizocilpine (MK-801), the competitive NMDA antagonist AP-7, and a glycine 
partial agonist (ACPC) (see box on NMDA receptors) in a murine variant of the 
forced swim test [22], a “behavioral despair” paradigm incorporating an 
inescapable stressor.  Each of these compounds produced a dose dependent 
reduction in immobility, a characteristic of prototypic ADs like imipramine.  Over 
the past twenty years, more than a dozen reports have appeared describing the 
AD-like properties of structurally diverse NMDA antagonists in rodent behavioral 
despair procedures. Thus, use dependent channel blockers (ketamine, 
memantine, dizocilpine), competitive antagonists (AP-7; CGP 37849), NR2B 
antagonists (see box on NMDA receptors) (eliprodil; Ro 25-6981), divalent cation 
site blockers (Mg++, Zn++) and glycine site antagonists and partial agonists (e.g., 
5,7-dichlorkynurenic acid; ACPC) have all been reported as active [23-25].  
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NMDA antagonists also exhibit AD-like properties in a chronic mild stress model 
[26,27] with greater face and construct validity [28,29] than the forced swim and 
tail suspension tests [30] that are recognized as “gold standards” to screen drugs 
for antidepressant activity. Thus, chronic administration of competitive and 
noncompetitive NMDA antagonists [26,27] are as effective as imipramine in 
reversing the deficits in sucrose consumption (used as an endpoint to model 
anhedonia) in this model.  Moreover, the glycine partial agonist ACPC was 
reported to exhibit a more rapid onset than typically observed with biogenic-
amine based agents [27], perhaps anticipating the rapid onset of antidepressive 
action reported after ketamine administration [31-35].  
NMDA antagonists are clinically effective ADs 
Ketamine infusion produces a rapid and robust AD response 
The initial clinical test of the hypothesis that NMDA antagonists are 
antidepressant compared a double blind infusion of ketamine (0.5 mg/kg) to 
saline in nine medication-free, depressed patients.  Ketamine produced dramatic 
reductions in Hamilton Depression Rating Scale (HAM-D scores within 3 h which 
were sustained for at least 3 days. The reductions (~15 points) in HAM-D scores 
normalized (i.e., to within 5 points of baseline) within 1-2 weeks of infusion.  A 
large, albeit transient (<2 h) spike in the visual analog scale produced by 
ketamine is potentially confounding, since perception of a drug effect could skew 
patient interviews and investigator ratings [34].  In a larger (17 patient) study of 
treatment resistant patients (individuals who failed to adequately respond to at 
least two AD regimens), a similar, rapid (within 2 h) improvement in depressive 
Comment [E11]: In glossary 
Comment [E12]: In glossary 
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symptoms was reported [31] following ketamine (0.5 mg/kg) infusion (Fig. 2).  
Within 24 h, 71% met response (defined as a 50% reduction in HAM-D score) 
and 29% met remission (a HAM-D score ≤ 7) criteria, with 35% of the maintaining 
a response for at least one week.  Ketamine also produced a transient spike in 
both the BPRS and the Young mania rating scale, which suggests that the active 
arm was apparent to both subject and investigator [31] . Two recent reports 
confirm the AD action of ketamine. In an open label study [32], ketamine (0.5 
mg/kg) infusion rapidly (<4 h) reduced depressive symptoms in treatment 
resistant patients.  In this patient population, individuals with a confirmed family 
history of alcohol abuse had significantly higher response (67%) and remission 
rates (42%) than patients with no family history (18% and 9%, respectively). In a 
second study [35], ketamine infusion (0.5) produced a rapid (within 24 h) and 
robust reduction (~22 points) in total MADRAS scores. Moreover, suicidal 
ideation was significantly reduced (p<0.001) in this cohort of 26 treatment 
resistant patients.  These latter findings indicate that ketamine may prove useful 
in acutely suicidal, depressed patients for whom conventional ADs provide little 
relief.   
Both the magnitude and onset of these AD effects are dramatic compared 
to SSRIs (Fig 2).  Thus, response rates following 6-8 week trials of SSRIs and 
other biogenic amine based agents are typically in the 60-70% range compared 
to 40-50% response with placebo [36-38].  Statistically significant differences 
usually take 2-3 weeks to emerge, and a 3 point separation in HAM-D scale 
scores between drug and placebo is considered clinically significant [39]. 
Comment [E14]: In glossary. 
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Clinical studies with memantine in depressed patients 
Despite the rapid and robust AD effects of ketamine, not all clinical studies 
with NMDA antagonists have yielded such dramatic results.  Memantine, at 
doses used to treat Alzheimer’s disease (5-20 mg/day), failed to separate from 
placebo (n=16 patients/arm) in an 8 week, double blind, placebo controlled trial 
[40].  In contrast, a small open label trial [41] that permitted titrated dosing up to 
40 mg/day reported a significant reduction in depressive symptomatology.  
However, this effect was apparent following the first week of memantine 
treatment at the same starting dose used in the failed study [40].  There were 
significant differences in study design (e.g., open label versus double blind, an 
option to increase dosing above 20 mg/day in the successful trial) which could 
contribute to the discrepant findings.  Perhaps trumping these differences in 
study design is the high failure rate in depression trials; it has been estimated 
that approved antidepressants fail to separate from placebo in about 50% of trials 
[38].  The NIH trial registry (www.clinicaltrials.gov) indicates that there are 
ongoing trials with memantine in depression, although a recent report has 
questioned whether brain concentrations of memantine are sufficient to block the 
predominant species of NMDA receptors (NR1/2A and NR1/2B)  under 
physiological conditions [42].  
Traxoprodil, a selective NR2B antagonist, is AD 
 A study with the NR2B selective antagonist traxoprodil (CP 101,606) in 
treatment resistant depression is noteworthy for both its design and results [43]. 
This placebo controlled, double blind study used patients who did not respond 
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adequately to at least one trial with an SSRI.  During the initial, open label phase, 
subjects received paroxetine for six weeks and at midpoint, a single intravenous 
placebo infusion.  Patients not responding to the SSRI were then randomized to 
receive a single (blinded) infusion of either traxoprodil or placebo with continued 
paroxetine treatment for an additional 4 weeks.  Patients receiving traxoprodil 
had a greater decrease in MADRAS total scores (8.6 points) compared with 
placebo. Moreover, the response rate to traxoprodil was 3-fold higher than 
placebo (60% vs 20%); 78% of traxoprodil treated patients who responded 
maintained this response for at least one week after infusion, and 32% 
maintained this response at 30 days post infusion. Contrary to expectations from 
preclinical findings [44], traxoprodil produced dissociative-like symptoms in an 
apparent dose dependent manner.  Nonetheless, this study [43]  indicates that 
the manifestation of dissociative symptoms is neither necessary nor sufficient for 
the antidepressant effect of traxoprodil since among the 6 patients experiencing 
dissociative symptoms, 4 met response criteria and 2 did not, while more than 
half of the traxoprodil treated subjects who did not experience dissociative 
symptoms met response criteria. Although this is a small study, the data indicate 
that it may be possible to achieve an acceptable AD response in depressed 
individuals absent dissociative symptoms by further reducing the dose of 
traxoprodil, Alternatively, multiple injections of lower doses might also achieve 
the desired separation of pharmacological effects.  Nonetheless, the hypothesis 
that dampening NMDA receptor function through a selective molecular 
mechanism will provide an acceptable safety profile for an AD has not been 
Comment [E18]: In glossary 
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proven.  Moreover, based on the dissonance between preclinical and clinical 
findings with traxoprodil, an adequate test of this hypothesis will demand a 
rigorous test in the clinic.  In June 2009, no active traxoprodil trials were listed on 
www.clinicaltrials.gov.  
Conclusions and Perspectives On The Development of Glutamate-based ADs 
Almost two decades elapsed between the demonstration that NMDA 
antagonists-possess AD like properties [20] and the announcement of an 
industrial program specifically designed to develop NMDA antagonists for 
depression.  By comparison, 13 years elapsed between the first paper describing 
the ability of fluoxetine to inhibit serotonin uptake [45] and the approval of 
Prozac® in 1987.  Certainly, absent compelling evidence for a significant clinical 
advantage over the SSRIs, it would be difficult to champion a mechanism already 
linked to dissociative side effects.  Further, during the 1990s, many 
pharmaceutical and biotechnology companies had programs to develop NMDA 
antagonists, most often targeting cerebral ischemia and neurodegenerative 
disorders [44]. There have been no reports of successful trials with NMDA 
antagonists in neurological indications (e.g. stroke and traumatic brain injury) 
(reviewed in [44,46]). Indeed, traxoprodil, which has now shown promise in 
treatment-resistant depression, failed in a traumatic brain injury study [44]. 
Nonetheless, with compounds already available, evidence that chronic treatment 
with biogenic-amine based agents dampens NMDA receptor function [23,47-49] 
and highly encouraging clinical results with ketamine and traxoprodil, drug 
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companies may now be set to repurpose NMDA antagonists for patients not 
responding to biogenic amine-based ADs.  
While less problematic than a course of electroconvulsive therapy, the 
commercial prospects for a parenterally administered AD, particularly an agent 
with the potential for producing dissociative effects, may be limited.  Assuming an 
orally active NMDA antagonist can be developed [50,51], or failing this, a 
parenterally administered agent lacking psychotomimetic effects, there are 
impediments to the development of a new chemical entity that were not at issue 
when ketamine was introduced almost a half century ago.  In addition to a 
potential for abuse liability, an NMDA antagonist indicated for depression 
(assuming episodic, subchronic administration over a lifetime) will be scrutinized 
in long term toxicology, carcinogenicity, and reproductive toxicity studies, among 
others.  Neuronal vacuolization in retrosplenial and cingulate cortex, observed 
following administration of dizocilpine and other NMDA antagonists [52], 
threatened the development of these compounds twenty years ago.  While this is 
likely a species specific phenomenon, the long term consequences of NMDA 
receptor blockade will receive careful attention.  
Alternative glutamate-based approaches  
Clinical studies with ketamine and traxoprodil have not resolved either 
how a single dose of an NMDA antagonist (particularly ketamine, with a half life 
of ~2 h) produces a long-lived AD effect [31] or the consequences of chronic drug 
administration on both efficacy [25,35,53] and side effects.  Addressing these 
latter issues in the clinic will be costly and may require a viable drug candidate 
Comment [E19]: I think the section in blue can 
be edited and amalgamated with the last section. 
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developed by a major pharmaceutical company. However, a preclinical report 
[25] demonstrating that AMPA receptor activation is required for the AD-like 
actions of ketamine and an NR2B antagonist (but see [54]) may provide insights 
into the apparently long-lived antidepressant effects of NMDA antagonists and 
offer alternative, glutamate-based approaches to treating depression. Thus, 
congruent with this report [25] AMPA receptor potentiators exhibit AD-like 
properties in preclinical models [55,56], and several of these molecules are in 
clinical development, including one recently concluded trial in depression 
sponsored by the NIH (www.clinicaltrials.gov).  Also consistent with the 
hypothesis that AMPA receptors are a viable target for developing glutamate-
based medications is the finding that the AD-like effects of metabotropic group II 
(mGlu2/3) antagonists are blocked by the AMPA receptor antagonist, NBQX [57].  
Moreover, chronic treatment with biogenic amine based ADs appears to both 
enhance AMPA receptor function by altering the phosphorylation state of specific 
AMPA receptor subunits [58] and increase the membrane expression of AMPA 
receptors [59]. 
Other promising glutamate-based strategies to treat depression have also 
emerged [60-62] from the heuristic framework [9,63] grounded on the AD 
properties of NMDA antagonists.  These approaches range from inhibitors of 
glutamate release and ions (Zn++, Mg++) inhibiting NMDA receptor function to 
modulation of metabotropic glutamate receptors [24,61,62,64,65].  Preliminary 
clinical results using several of these approaches in treatment resistant 
depression [60,66,67] have been encouraging, and will undoubtedly catalyze 
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additional studies. Modulation of glutamatergic transmission by regulating 
receptor expression, trafficking, and turnover [56,61,62] as well as a fuller 
understanding of the downstream biological cascades initiated by modulation of 
ionotropic and metabotropic glutamate receptors [56,62] may provide additional 
avenues for developing safe and effective antidepressants.  In view of the current 
conservative regulatory environment, a high safety bar will be demanded of 
NMDA antagonists and other potential ADs affecting glutamatergic transmission 
[56,61,62] as long alternative therapies, however imperfect, are available. 
Nonetheless, for those patients unresponsive to biogenic amine-based agents, 
NMDA antagonists hold the promise of a new therapeutic option.  
 14 
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Figure Legends 
 
Figure 1) From bench to bedside: key observations leading to the development of 
NMDA antagonists as antidepressants 
A) Chronic exposure to uncontrollable and inescapable stressors are etiological 
factors in the development of affective disorders (Seligman [17]).  B) These 
stressors alter the turnover of biogenic amines, the primary targets of “classical” 
antidepressants (Weiss et al., [15]).  C) Chronic (but not acute) treatment with 
monoamine-based antidepressants prevents the behavioral deficits caused by 
uncontrollable stressors (Sherman, et al. [19]).  D) Uncontrollable stressors (like 
those used to produce a learned helplessness syndrome) disrupt LTP (Shors et 
al., [12]), one of the molecular substrates of neural plasticity that is dependent on 
E) NMDA receptors (Harris et al., [13]). F) Based on these previous observations, 
it was hypothesized that direct modulation of NMDA receptor function would 
produce an effective antidepressant response (Trullas and Skolnick, [20]).  G) 
Chronic, but not acute treatment with structurally diverse antidepressants (e.g., 
SSRIs, TCAs, MAOIs) as well as electroconvulsive shock produce adaptive 
changes in NMDA receptors consistent with a reduction in function.  These 
findings led to the hypothesis that NMDA receptors are a final common target for 
antidepressants (reviewed in Skolnick et al., [47]). H and I) The clinical proof of 
principle study designed to test hypothesis that NMDA antagonists are 
antidepressant (Berman et al., [34] and Zarate et al., [31]). 
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Figure 2) Antidepressant actions of: (a) ketamine and (b) SSRIs in double blind, 
placebo controlled trials:  Panel A illustrates changes in HAM-D21 scores in a 
double blind trial of a single intravenous infusion of ketamine (0.5 mg/kg) versus 
placebo in treatment resistant patients (see text for details).  Symbols: *, p<0.05; 
┼, p<0.01; ╪, p<0.001 versus placebo. These data were abstracted from Zarate, 
et al. [31] with permission of the author.  Panel B illustrates a double blind, 
placebo controlled trial of two SSRIs (citalopram and sertraline) in depressed 
patients. Note that treatment resistant patients were excluded from this study.  
Baseline HAM-D17 scores in this study ranged between 26.4-26.6. At endpoint, 
both SSRIs separated from placebo by 3-4.5 points. Reprinted from Stahl et al., 
[68], with permission. Note the difference in time scale between panels. 
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TEXT BOX: NMDA RECEPTORS  
 
NMDA receptors are a family of ionotropic glutamate receptors that are 
distributed throughout the mammalian central nervous system. These ligand-
gated ion channels are unique in several respects, including a requirement for 
co-agonist binding to effect channel activation and, at resting membrane 
potential, blockade of this cation channel by Mg++.  Membrane depolarization 
relieves this block, and in the presence of co-agonists glutamate and glycine (or 
D-serine, another endogenous ligand of the glycine site), the cation channel is 
opened, allowing Ca++ and Na+ to enter the cell. Two principal subunit families, 
NR1 and NR2, as well as a modulatory subunit, NR3, have been identified. 
NMDA receptors are likely formed as tetramers consisting of two NR1 and two 
NR2 subunits. NR3 subunits are unable to form homomeric receptors, but 
coexpression of NR3 with NR1 and NR2 subunits results in an NMDA receptor 
with altered response characteristics. Four NR2 subunits (A, B, C and D) and 
eight splice variants of NR1 have been identified.  With multiple sites for 
pharmacological intervention, a large number of tools have been developed to 
study NMDA receptors. Thus, competitive antagonists of both the glutamate (e.g. 
AP-7) and glycine (e.g., 5,7-dichlorokynurenic acid) sites have been available for 
more than two decades. Moreover, compounds with partial agonist properties at 
the glycine site (D-cycloserine, HA-966, ACPC) have been identified. 
Uncompetitive NMDA antagonists such as ketamine, memantine and MK-801 
(also known as use-dependent channel blockers) bind at sites within the ion 
channel. The apparent potency, speed and voltage-dependence of these 
uncompetitive NMDA antagonists is influenced by subunit composition and 
antagonist affinity. Polyamines such as spermine and spermidine have multiple 
effects at NMDA receptors, acting as positive (allosteric) modulators binding to 
NR2B subunits, and at higher concentrations acting as channel blockers. Several 
highly selective NR2B antagonists have been identified, including the prototypic 
ifenprodil, and traxoprodil (CP 101,606), which has been reported to improve 
depressive symptoms in patients resistant to biogenic-amine based agents. 
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Glossary 
Inescapable stressor: An uncontrollable and/or unpredictable stimulus that 
triggers an unconditioned behavioral response (fight or flight) which does not 
permit successful avoidance and can produce behavioral depression.  
Forced swim test: A behavioral paradigm in which rats [69] or mice [22] are 
forced to swim in an environment from which there is no escape (a narrow, water 
filled cylinder).  After an initial period of vigorous activity during which the rodent 
attempts to escape, there is a period of relative immobility, with the subject 
making only those minimal movements necessary to stay afloat.  Acute 
antidepressant treatment reduces the time spent immobile.  The forced swim test 
is highly predictive of antidepressant activity.  It is generally considered the “gold 
standard” for screening putative antidepressants.   
Imipramine:  The prototypic “tricyclic” (dibenzazepine) antidepressant. 
Imipramine was introduced into therapy more than 50 years ago, but its use has 
been curtailed by the availability of safer (but not more effective) compounds. 
Imipramine blocks the uptake of both serotonin and norepinephrine.  
Chronic mild stress model: An animal model of depression that appears to satisfy 
the criteria of face, construct, and predictive validity.  Rats or mice are subjected 
to a variety of mild inescapable stressors that change every few hours over a 
period of weeks or months.  This procedure produces multiple behavioral 
changes [29], including a reduction in the sensitivity to reward, often monitored 
as a reduction in either the consumption or preference for a palatable solution 
such as sucrose or saccharin.  The reduction in sensitivity to reward is thought to 
simulate anhedonia (an inability to experience pleasant events), a core symptom 
of depression.  Many of the effects of chronic mild stress, including the reduction 
in sensitivity to reward, are reversed by antidepressants. 
Tail suspension test:  A behavioral paradigm [70] that measures the time mice 
spend immobile after being suspended by the tail.  After an initial period of 
vigorous struggling, there is a period of relative immobility.  Acute antidepressant 
treatment reduces the time spent immobile. Like the forced swim test, the tail 
suspension test is often used to screen putative antidepressants.  Despite a face 
value similarity, the neurochemical pathways involved in mediating performance 
in the forced swim and tail suspension tests are not identical [71].  
Learned Helplessness: A model of depression originally described in dogs [72] 
and later extended to laboratory rodents and humans, relies on the observation 
that subjects exposed to uncontrollable stress exhibit performance deficits in 
subsequent learning tasks.  These deficits are not observed in subjects exposed 
to the identical stressor but able to control it [73].  In addition to the passivity, 
“helpless” subjects demonstrate a variety of behavioral alterations including 
decreased general activity, diminished performance in appositively motivated 
tasks, decreased aggression and loss of appetite.  The current protocol for 
learned helplessness involve the use of triadic design (escapable shock, yoked-
inescapable shock, and restrained control): the escape group has the opportunity 
to terminate the stress, while the yoked subject cannot escape it.  Performance 
deficits resulting from exposure to uncontrollable stress can be reversed by 
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subchronic (4-7 days) treatment with antidepressants [74].  
HAM-D (Hamilton Depression Rating Scale): A clinician administered rating scale 
usually containing 17-21 multiple choice questions [75,76].  This instrument rates 
the severity of symptoms commonly manifested in depressed individuals.  The 
HAM-D is frequently used for rating the severity of depression and drug-induced 
changes in depressive symptomatology in clinical trials.  
BPRS (brief psychiatric rating scale): A clinician-administered instrument (often 
used in drug trials to measure antipsychotic efficacy) assesses the severity level 
of 18 symptom constructs (e.g., hallucinations, suspiciousness) in subjects with 
moderate to severe psychoses. 
Young Mania rating scale: A clinician administered, 11-item instrument [77] used 
to assess the severity of manic episodes. 
MADRAS (Montgomery Asberg Depression Rating Scale): A clinician 
administered questionnaire which, like the HAM-D, measures symptom severity 
in depressed patients.  The MADRAS was designed [78] to be more sensitive 
than the HAM-D to drug induced changes in depressive symptomatology. 
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We thank the reviewers for their insights and comments. We have incorporated their 
suggestions/comments into the manuscript as detailed below. 
 
Reviewer #1 
1) We share the reviewer’s enthusiasm for AMPA potentiation. We did not expand this 
area in the original manuscript because of our desire to focus on preclinical studies directly linked 
to mechanisms with published data in depressed individuals. We were also mindful of the word 
limit of an Opinion piece in TIPS. However, based on the reviewer’s comments, we have 
integrated both of the suggestions in the area corresponding to p. 9 of the original manuscript 
where AMPA potentiation had been discussed only briefly.  
2) The reviewer is correct that there are no clear answers to the queries raised with 
respect to separating therapeutic and dissociative effects.  On p.6 of the original manuscript, we 
stated: “The hypothesis that dampening NMDA receptor function through a particular molecular 
mechanism will provide a better safety profile at antidepressant doses requires rigorous testing in 
the clinic.”  We have now expanded a discussion of this issue, reminding the reader that the 
ability to capitalize on the remarkable clinical findings with NMDA antagonists will ultimately be 
defined by the safety profile of these compounds.  With respect to the specific comment regarding 
administration of a counter-agent/rescue medication that might reduce the emergence of 
dissociative effects while sparing the therapeutic effect: the development/regulatory path for 
giving two drugs (e.g. either two novel compounds or a novel and already approved compound) is 
far more tortuous than for a single compound.  It is unlikely that a major pharmaceutical company 
would expend resources on developing such a combination, particularly if one of the agents (e.g. 
ketamine) were not patent protected. The discussion of exploiting an understanding of potential 
downstream biological cascades to develop novel targets is fascinating, but well beyond the 
scope of this Opinion piece. We have inserted a phrase corresponding to p.9 of the original 
manuscript acknowledging the importance of this research area.    
3) We thank the reviewer for his comment and insights with respect to Figure 1 (“From 
bench to bedside: key observations leading to the development of NMDA antagonists as 
antidepressant “).  When originally formulating this figure, we struggled with a way to integrate 
and summarize the key findings leading up to the seminal 1990 report that NMDA antagonists 
exhibit antidepressant like actions and subsequent studies emerging from these findings, 
including the demonstration (in 2000) that an NMDA antagonist is antidepressant.  As may be 
inferred from the figure title, this information was not meant to strictly convey a timeline (since the 
studies catalyzing the 1990 report came from disparate fields and did not follow a strict timeline), 
but rather the thinking (with the dates provided for instructive purposes) behind these seminal 
studies. The original figure was meant to capture these concepts, but based on the reviewer’s 
comments clearly can be improved.  We have revised the figure, literally “opening it up” to more 
clearly illustrate the key findings, links between these findings, and dates associated with this 
corpus of work. The Figure legend (which has not been altered) remains alphabetically keyed to 
guide the reader through the studies leading up to the hypothesis that NMDA antagonists could 
be antidepressant and the first clinical test of this hypothesis.   
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p.7: citation added. 
 
Reviewer #2 
1) The abstract has been revised, including the last sentence. 
2) While assembling the first draft of the manuscript, we discussed redrawing the figures to 
align ordinates, but decided to use the originals. First, the dramatic difference in scaling 
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